NEW YORK, Sept. 28 (GenomeWeb News) - International Therapeutics has granted to Rosetta Inpharmatics a worldwide nonexclusive license to its ProxiQuant technology for research and development applications, IT said today.
ProxiQuant is an enzymatic application that enables stoichiometric generation of surrogate DNA targets from primary RNAi molecules in biological samples, IT said. As opposed to RT-PCR, ProxiQuant uses ligases to create larger DNA molecules from smaller RNAi, which can then be quantified using several methods.
Financial details of the agreement were not disclosed.